Antibiotic Treatment Guidelines

Introduction to Antibiotic Treatment

• Antibiotic treatment is effective for various infections, including respiratory and gastrointestinal infections, according to the Centers for Disease Control and Prevention (CDC) 1

Patient Assessment and Prevention

• Healthy individuals traveling to southern Africa should not use routine antibiotic prophylaxis to prevent traveler's diarrhea, as it can promote drug-resistant organisms and have adverse effects, according to the CDC 2
• To prevent traveler's diarrhea, the CDC recommends avoiding raw fruits and vegetables, raw or undercooked seafood or meat, items sold by street vendors, and unpasteurized milk and dairy products 2
• Safe beverages include bottled beverages, hot coffee and tea, beer and wine, and water brought to a rolling boil for >1 minute, as suggested by the CDC 2
• Tap water should be treated with iodine or chlorine, or boiled for >1 minute, to make it safe for consumption, as recommended by the CDC 2
• The CDC advises avoiding swallowing water during swimming, especially in potentially contaminated water, to prevent traveler's diarrhea 2

Diagnosis and Treatment

• Loperamide (Imodium) should not be used if high fever or blood in stool is present, and should be discontinued if symptoms persist >48 hours, according to the CDC 2
• Patients should seek medical attention if diarrhea is severe and doesn't respond to empiric therapy, stools contain blood, fever is accompanied by shaking chills, or dehydration occurs, as recommended by the CDC 2
• For mild dehydration, the American Academy of Pediatrics suggests administering 50 mL/kg of oral rehydration solution (ORS) over 2-4 hours, while moderate dehydration requires 100 mL/kg of ORS over 2-4 hours 3
• Patients with severe dehydration (≥10% fluid deficit) should receive immediate IV fluids, as it is a medical emergency requiring prompt attention, as recommended by the CDC 3
• The following table summarizes the recommended treatment regimens:

• Azithromycin is recommended as first-line therapy for dysentery, regardless of geographic region, with high-level evidence 4
• Azithromycin has shown superior clinical cure rates compared to levofloxacin in areas with high fluoroquinolone resistance, with a dose of 1g single dose or 500mg daily for 3 days 4
• The Infectious Diseases Society of America recommends Azithromycin as the first choice for treatment, with a dosage of 10 mg/kg per day for 5 days for infants <6 months, and 10 mg/kg (maximum: 500 mg) on day 1, followed by 5 mg/kg per day (maximum: 250 mg) on days 2-5 for children >6 months 5

Diagnostic Tests

• Adequate diagnosis requires a direct examination of fresh stool samples, molecular tests for rapid results, and stool culture to identify the etiologic agent and its antimicrobial sensitivity, as recommended by the CDC 6
• The following table summarizes the recommended diagnostic tests:

• Microbiologic testing of stool is indicated for persistent symptoms (>1 week) and those who fail empiric therapy, and should include stool culture for bacterial pathogens, ova and parasite examination, Giardia and Cryptosporidium antigen testing, and Clostridium difficile testing, as recommended by the Journal of Travel Medicine and Clinical Infectious Diseases guidelines 4, 7

Special Populations

• HIV-infected travelers are at higher risk for foodborne and waterborne infections, according to the CDC 2, 8
• Immunocompromised patients with severe illness and bloody diarrhea should consider empiric antibacterial treatment with azithromycin, as suggested by the Infectious Diseases Society of America 5
• The World Health Organization recommends continuing breastfeeding for infants and resuming normal diet as soon as rehydration is achieved, as well as replacing ongoing losses with ORS: 10 mL/kg for each watery stool and 2 mL/kg for each episode of vomiting 3

Antibiotic Resistance and Surveillance

• Rising resistance to fluoroquinolones necessitates ongoing surveillance and appropriate antibiotic selection, with resistance rates to ceftriaxone reaching 14.2% in Asia-Africa after 2007, and resistance to nalidixic acid and ciprofloxacin in Asia-Africa progressively increasing each year 9
• Emerging resistance to azithromycin has been reported, with resistance mechanisms including mph(A), erm(B), and erm(42) genes, emphasizing the need for continued monitoring of resistance patterns 7